Artificial intelligence has been a big theme in the world of health and medical research, and specifically in the area of drug discovery. Causaly, a London startup that has built an AI platform to help researchers accelerate the development and testing of drugs, has raised $60 million, a Series B that will be going toward R&D and to continue building out its team. ICONIQ Growth the growth-stage fund affiliated with the iconic investment firm of the same name is leading the round, with previous backers Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club also participating.
BERKELEY, CA and TEL AVIV, Israel (PRWEB) April 13, 2023 Otterize, an open-source solution that’s re-inventing how to connect services securely, to each
POLITICO Pro Morning Tech UK: TikTok ban next steps — Budget fallout day 2 — OSB a year on politico.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.eu Daily Mail and Mail on Sunday newspapers.
Fintech Gotrade Secures $15 5M for Fractional Share Trading Platform crowdfundinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from crowdfundinsider.com Daily Mail and Mail on Sunday newspapers.